News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.


Media Contact:

Robert Murphy

Director, External Communications,
Otsuka America Pharmaceutical, Inc

Press Release

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The decision to continue the trial is based on the results of an independent interim analysis, supporting to progress the trial to the planned full enrollment of 330 patients.

Press Release

Otsuka Pharmaceutical Co., Ltd. announces that its collaborator Akebia Therapeutics, Inc. has submitted a New Drug Application to the Food and Drug Administration in the U.S. seeking approval for Akebia’s investigational drug vadadustat as an oral medication for the treatment of renal anemia due to chronic kidney disease in adult patients who receive dialysis and those who do not receive dialysis.

Press Release

Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Click Therapeutics, Inc. announce the initiation of the Mirai study, a landmark fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with major depressive disorder (MDD) who are on antidepressant monotherapy.

US News

The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces it has entered a collaboration agreement with Eikonizo Therapeutics, Inc., a biotechnology company committed to creating life-changing therapies, to develop inhibitors of histone deacetylase-6 (HDAC6) focused on treating amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, and other diseases.